翰森制药产品昕越新适应症获NMPA纳入优先审评审批程序

财中社
10 Feb

财中社2月10日电翰森制药(03692)发布公告,宣布其产品昕越®(伊奈利珠单抗注射液)因全球关键性III期试验MITIGATE的积极结果,用于治疗免疫球蛋白G4相关性疾病(IgG4-RD)的新适应症于2025年2月8日被国家药品监督管理局(NMPA)纳入优先审评审批程序。昕越®于2019年5月24日与Viela Bio签订了许可协议,获得在中国内地、香港和澳门开发及商业化的独家许可。该产品于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10